Loy­ola is work­ing on a new and im­proved CAR-T prod­uct, look­ing to over­come high-fre­quen­cy side ef­fects

Loy­ola Uni­ver­si­ty Chica­go thinks it can do a bet­ter job mak­ing CAR-T ther­a­pies for pa­tients. And now it has the mon­ey to launch a pi­lot pro­gram to do just that.

These cell ther­a­pies re­ly on cells ex­tract­ed from pa­tients, reengi­neered in­to at­tack ve­hi­cles point­ed at can­cer cells and then re-in­fused in­to pa­tients as ther­a­py. Up un­til now, Loy­ola has been us­ing the CAR-T drugs on the mar­ket from No­var­tis and Gilead/Kite. But once it starts up its own man­u­fac­tur­ing op­er­a­tion, it plans to make it avail­able in Chica­go and “be­yond.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.